{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T21:49:18Z","timestamp":1793137758285,"version":"4.5.0"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Urticarial vasculitis (UV) is a rare autoimmune condition characterized by persistent urticarial lesions with underlying small vessel leukocytoclastic vasculitis. It often presents with systemic symptoms and poses therapeutic challenges, especially in refractory cases. We report the case of a 39-year-old woman who presented with recurrent episodes of widespread, painful wheals lasting more than 24\u202fh, along with arthralgia, myalgia, blurred vision, and fatigue. Her diagnosis was confirmed by skin biopsy, and she failed multiple lines of immunosuppressive and biologic therapies, including corticosteroids, colchicine, omalizumab, dapsone, rituximab, mycophenolate mofetil, and cyclosporine. After initiating treatment with Upadacitinib 30\u202fmg daily orally, in combination with omalizumab and dapsone, she experienced a dramatic clinical improvement within one month, with near-complete resolution of cutaneous lesions and significant relief of systemic symptoms. This case highlights the potential role of JAK inhibitors, particularly Upadacitinib, as a novel therapeutic option in managing refractory urticarial vasculitis. Further studies are needed to evaluate its long-term efficacy and safety in this context.<\/jats:p>","DOI":"10.3389\/fmed.2025.1669513","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:14Z","timestamp":1756181594000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Case Report: Upadacitinib in the management of refractory urticarial vasculitis"],"prefix":"10.3389","volume":"12","author":[{"given":"Maan M.","family":"Almaghrabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen","family":"Kalantan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alhusain","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulhadi","family":"Jfri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.iac.2004.01.007","article-title":"Urticarial vasculitis and hypocomplementemic urticarial vasculitis syndrome","volume":"24","author":"Davis","year":"2004","journal-title":"Immunol Allergy Clin N Am"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jaci.2018.09.007","article-title":"Treatment of urticarial vasculitis: a systematic review","volume":"143","author":"Kolkhir","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","article-title":"Upadacitinib: mechanism of action, clinical, and translational science","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"286","DOI":"10.12932\/AP-050918-0402","article-title":"Successful treatment of normocomplementemic urticarial vasculitis with omalizumab: a report of three cases and literature review","volume":"38","author":"Rattananukrom","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"e15932","DOI":"10.1111\/dth.15932","article-title":"Efficacy of oral tofacitinib in refractory chronic spontaneous urticaria and urticarial vasculitis","volume":"35","author":"Mansouri","year":"2022","journal-title":"Dermatol Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"904","DOI":"10.2340\/00015555-3006","article-title":"Efficacy of oral ruxolitinib in a patient with refractory chronic spontaneous urticaria","volume":"98","author":"Fukunaga","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5139","DOI":"10.5826\/dpc.1502a5139","article-title":"Upadacitinib for treatment-resistant urticarial Vasculitis: a case study and therapeutic insight","volume":"15","author":"Falcinelli","year":"2025","journal-title":"Dermatol Pract Concept"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/nmqrck","article-title":"Successful treatment with upadacitinib in a patient with intractable urticarial vasculitis: a case report","author":"Xie","year":"2025","journal-title":"Clin Exp Rheumatol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"695768","DOI":"10.3389\/fimmu.2021.695768","article-title":"Tofacitinib treatment of refractory cutaneous leukocytoclastic vasculitis: a case report","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"674709","DOI":"10.1155\/2014\/674709","article-title":"Pathogenesis of chronic urticaria: an overview","volume":"2014","author":"Jain","year":"2014","journal-title":"Dermatol Res Pract"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669513\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T04:13:14Z","timestamp":1756181594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1669513\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":11,"alternative-id":["10.3389\/fmed.2025.1669513"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1669513","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]},"article-number":"1669513"}}